Skip to Content


Active Substance: epoetin delta
Common Name: epoetin delta
ATC Code: B03XA
Marketing Authorisation Holder: Shire Pharmaceutical Contracts Limited
Active Substance: epoetin delta
Status: Withdrawn
Authorisation Date: 2002-03-18
Therapeutic Area: Anemia Kidney Failure, Chronic
Pharmacotherapeutic Group: Antianemic preparations

Therapeutic Indication

Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.

The marketing authorisation for Dynepo has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.